Entrectinib: full analysis of dosage forms, usage and medical applications

Entrectinib (Entrectinib), as a highly efficient ATP competitive and selective tyrosine kinase inhibitor, has significant effects on Trk A, B, C, ALK and ROS1 kinases. This drug was developed by Roche. Since 2019, it has been successively approved in Japan, the United States and other places for the treatment of patients with NTRK fusion-positive relapsed or advanced solid tumors, both in children and adults. At the same time, it is also approved for the treatment of patients with ROS1-positive non-small cell lung cancer.

Enrectinib comes in two forms: capsules and granules. The capsules are available in two specifications: 100mg yellow opaque HPMC capsules and 200mg orange opaque HPMC capsules. In addition, entrectinib is also available in the form of oral granules, which are presented as brown-orange or gray-orange round film-coated granules. Each packet contains 50 mg of entrectinib. When storing, it is recommended to keep the medicine at 20°C to 25°C and ensure that the container is tightly closed to prevent moisture.

It is worth mentioning that entrectinib capsules can also be prepared into oral suspensions using drinking water or milk, but this process should be carried out under the guidance of a doctor, and the storage time of the prepared suspension should not exceed 2 hours, and the storage temperature should be below 30°C.

Entrectinib is a prescription drug and its treatment should be carried out under the guidance of a doctor experienced in cancer drug treatment. For adult patients, the recommended daily dose is 600 mg in one dose. The dosage for children needs to be determined based on their height and weight. Treatment should be continued until the effects of the drug cease. If certain side effects occur during treatment, your doctor may adjust the dose, interrupt or stop treatment entirely.